Prognostic Significance of Plasma Placental Growth Factor Levels in Renal Cell Cancer: An Association with Clinical Characteristics and Vascular Endothelial Growth Factor Levels

Anticancer Research

Volumn 23, Issue 6 D, 2003, Pages 4953-4958

  Matsumoto, Kazuhisa ^a   Suzuki, Kazuhiro ^a   Koike, Hidekazu ^a   Okamura, Keigo ^a   Tsuchiya, Kiyotaka ^a   Uchida, Tatsuya ^b   Takezawa, Yutaka ^b   Kobayashi, Mikio ^b   Yamanaka, Hidetoshi ^a  

^a GUNMA UNIVERSITY   (Japan)

^b National Hospital Organization   (Japan)

Author keywords

Placental growth factor; Prognosis; Renal cell cancer; Vascular endothelial growth factor

Indexed keywords

ANGIOGENIC FACTOR; GROWTH FACTOR; PLACENTAL GROWTH FACTOR; UNCLASSIFIED DRUG; VASCULOTROPIN;

ADULT; AGED; ANGIOGENESIS; ARTICLE; CANCER GRADING; CANCER INVASION; CLINICAL ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; FEMALE; HORMONE BLOOD LEVEL; HUMAN; HUMAN TISSUE; KIDNEY CANCER; MALE; METASTASIS; MULTIVARIATE ANALYSIS; PLACENTAL GROWTH FACTOR BLOOD LEVEL; PRIORITY JOURNAL; PROGNOSIS; PROSPECTIVE STUDY; TUMOR BLOOD FLOW; VASCULOTROPIN BLOOD LEVEL;

CARCINOMA, RENAL CELL; CASE-CONTROL STUDIES; FEMALE; HUMANS; KIDNEY NEOPLASMS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOVASCULARIZATION, PATHOLOGIC; PREGNANCY PROTEINS; PROGNOSIS; SURVIVAL RATE; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 0842343498     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (30)

1. Folkman J: Tumor angiogenesis. Adv Cancer Res 43: 175-203, 1985.
2. Weidner N: Intratumoral microvessel density as a prognostic factor in cancer. Am J Pathol 147: 9-19, 1995.
3. Folkmann J: Clinical applications of research on angiogenesis. N Engl J Med 333: 1757-1763, 1995.
4. Czubayko F, Smith RV, Chung HC and Wellstein A: Tumor growth and angiogenesis induced by a secreted binding protein for fibroblast growth factor. J Biol Chem 269: 28243-28248, 1994.
5. Dosquet C, Coudert MC, Lepage E, Cabane J and Richard F: Are angiogenetic factors, cytokines, and soluble adhesion molecules prognostic factors in patient with renal cell carcinoma? Clin Cancer Res 3: 2451-2458, 1997.
6. Sato K, Tsuchiya N, Sasaki R, Shimoda N, Satoh S, Ogawa O and Kata T: Increased serum levels of vascular endothelial growth factor in patients with renal cell carcinoma. Jpn J Cancer Res 90: 874-879, 1999.
7. Wechsel HW, Bichler KH, Feil G, Loeser W, Lahme S and Petri E: Renal cell carcinoma: Relevance of angiogenetic factors. Anticancer Res 19: 1537-1540, 1999.
8. Jacobsen J, Rasmuson T, Grankvist K and Ljungberg B: Vascular endothelial growth factor as prognostic factor in renal cell carcinoma. J Urol 163: 343-347, 2000.
9. Persico MG, Vincenti V and DiPalma T: Structure, expression and receptor-binding properties of placenta growth factor (PIGF). Curr Top Microbiol Immunol 237: 31-40, 1999.
10. Maglione D, Guerriero V, Viglietto G, Delli-Bovi P and Persico MG: Isolation of a human placenta cDNA coding for a protein related to the vascular permeability factor. Proc Natl Acad Sci USA 88: 9267-9271, 1991.
11. DiSalvo J, Bayne ML, Conn G, Kwok PW, Trivedi PG, Soderman DD et al: Purification and characterization of a naturally occurring vascular endothelial growth factor, placenta growth factor heterodimer. J Biol Chem 270: 7717-7723, 1995.
12. Ziche M, Maglione D, Ribatti D, Morbidelli L, Lago CT, Battisti M et al: Placenta growth factor-1 is chemotactic mitogenic, and angiogenic. Lab Invest 76: 517-531, 1997.
13. Dull RO, Yuan J, Chang YS, Tarbell RK, Jain RK and Munn LL: Kinetics of placenta growth factor / vascular endothelial growth factor synergy in endothelial hydraulic conductivity and proliferation. Microvasc Res 61: 203-210, 2001.
14. Nomura M, Yamagishi S, Harada S, Yamashima T, Yamashita J and Yamamoto H: Placenta growth factor (PIGF) mRNA expression in brain tumors. J Neuro Oncol 40: 123-130, 1998.
15. Viglietto G, Maglione D, Rambaldi M, Cerutti J, Romano A, Trapasso F et al: Up-regulation of vascular endothelial growth factor (VEGF) and downregulation of placenta growth factor (PIGF) associated with malignancy in human thyroid tumors and cell lines. Oncogene 11: 1569-1579, 1995.
16. Takahashi A, Sasaki H, Kim SJ, Tobisu K, Kakizoe T, Tsukamoto T et al: Markedly increased amounts of messenger RNAs for vascular endothelial growth factor and placenta growth factor in renal cell carcinoma associated with angiogenesis. Cancer Res 54: 4233-4237, 1994.
17. Sobin LH and Wittekind CH (Eds.): International Union Against Cancer (UICC): TMN Classification of Malignant Tumors, 5th Ed, Wiley-Liss, New York, 1997 pp. 180-182.
18. Mostofi FK, Davis CJ, Sobin LH, Aizawa S, Delahunt B, Holzner JH et al: WHO International Histological Classification of Tumors: Histological Typing of Kidney Tumors, 2nd Ed, 1998 pp. 9-12.
19. Donnini S, Machein MR, Plate KH and Weich HA: Expression and localization of placenta growth factor and PIGF receptors in human meningiomas. J Pathol 189: 66-71,1999.
20. Lamszus K, Lengler U, Schmidt NO, Stavrou D, Ergün S and Westphal M: Vascular endothelial growth factor, hepatocyte growth factor/scatter factor, basic fibroblast growth factor, and placenta growth factor in human meningiomas and their relation to angiogenesis and malignancy. Neurosurgery 46: 939-948, 2000.
21. Lacal PM, Failla CM, Pagani E, Odorisio T, Schietroma C, Falcinelli S et al: Human melanoma cells secrete and respond to placenta growth factor and vascular growth factor. L Invest Delmatol 115: 1000-1007, 2000.
22. Eriksson A, Cao R, Pawliuk R, Berg SM, Tsang M, Zhou M et al: Placental growth factor-1 antagonized VEGF-induced angiogenesis and tumor growth by the formation of functionally inactive PlGF-1/VEGF heterodimers. Cancer Cell 1: 99-108, 2002.
23. Takahashi A, Sasaki H, Kim SJ, Kakizoe T, Miyao N, Sugimura T et al: Identification of receptor genes in renal cell carcinoma associated with angiogenesis by differential hybridization technique. Biochem Biophys Res Commun 257: 855-859, 1999.
24. Kondo S, Asano M, Matsuo K, Ohmori I and Suzuki H: Vascular endothelial growth factor/vascular permeability factor is detectable in the sera of tumor-bearing mice and cancer patient. Biochim Byophys Acta 1221: 211-214, 1994.
25. Webb NJA, Bottomley MJ, Watson CJ and Brenchley PEC: Vascular endothelial growth factor (VEGF) is released from platelets during blood clotting: implications for measurement of circulating VEGF levels in clinical disease. Clin Sci 94: 395-404, 1998.
26. Möhle R, Green D, Moore MAS, Nachman RL and Rafii S: Constitutive production and thrombin-induced release of vascular endothelial growth factor by human megakaryocytes and platelets. Proc Natl Acad Sci USA 94: 663-668, 1997.
27. Salgado R, Vermeulen PB, Benoy I, Weytjens R, Huget P, Van Marck E and Dirix LY: Platelet number and interleukin-6 correlate with VEGF but not with bFGF serum level of advanced cancer patients. Br J Cancer 80: 892-897, 1999.
28. Verheul HMW, Hoekman K, Luykx-de Bakker S, Eekman CC, Broxterman HJ and Pinedo HM: Platelet: transporter of vascular endothelial growth factor. Clin Cancer Res 3: 2187-2190, 1997.
29. Jelkmann W: Pitfalls in measurement of circulating vascular endothelial growth factor. Clin Chem 47: 617-623, 2001.
30. Houck KA, Ferrara N, Winer J, Cachianes G, Li B and Leung DW: The vascular endothelial growth factor family: identification of a fourth molecular species and characterization of alternative splicing of RNA. Mol Endocrinol 5: 1806-1814, 1991.